Patents by Inventor Richard D. DiMarchi

Richard D. DiMarchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200360530
    Abstract: Disclosed herein are modified C-terminal fragments of FGF21 optimized for binding to Klotho ? or antagonizing FGF21 activity. FGF21 peptides modified to comprise modifications to the C-terminal amino acid sequence are disclosed that have enhanced activity at the FGF21 receptor. Additionally, conjugates formed between the optimized FGF21 peptide fragments and insulin like peptides or nuclear hormone receptor ligands are provided.
    Type: Application
    Filed: August 3, 2020
    Publication date: November 19, 2020
    Inventors: Richard D. DiMARCHI, Alexei KHARITONENKOV, Pengyun LI, Archita S. AGRAWAL
  • Patent number: 10730923
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: August 4, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, David L. Smiley
  • Patent number: 10696726
    Abstract: Disclosed herein are insulin agonist peptides conjugated to a glucagon analog wherein the insulin/glucagon conjugate is targeted to liver tissues upon administration to a patient.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 30, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Todd Parody, Jie Han, Pengyun Li
  • Patent number: 10683334
    Abstract: Modified glucagon peptides are disclosed having improved solubility and/or stability while retaining glucagon agonist activity. The glucagon peptides have been modified by the substitution of pyridyl-alanine for a native amino acid at one or more of positions 6, 10 or 13 and/or substitution with an amino acid in the D-conformation at position 20 or 21 compared to native glucagon.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 16, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, John P. Mayer, Piotr Mroz
  • Publication number: 20190388510
    Abstract: Provided herein are glucagon agonist peptides conjugated with thyroid hormone receptor ligands that are capable of acting at the thyroid hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes, obesity, metabolic syndrome and chronic cardiovascular disease, comprising administering the conjugates of the invention.
    Type: Application
    Filed: May 26, 2017
    Publication date: December 26, 2019
    Inventors: Richard D. DIMARCHI, Brian FINAN, Bin YANG, Zhimeng ZHU
  • Publication number: 20190290772
    Abstract: Provided herein are GLP-1 agonist peptides conjugated with thyroid hormone receptor ligands that are capable of acting at the thyroid hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes, obesity, metabolic syndrome and chronic cardiovascular disease, comprising administering the conjugates of the invention.
    Type: Application
    Filed: May 26, 2017
    Publication date: September 26, 2019
    Inventors: Richard D. DIMARCHI, Brian FINAN, Bin YANG, Zhimeng ZHU
  • Patent number: 10385107
    Abstract: Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half-lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: August 20, 2019
    Assignee: Indiana Univeresity Researc and Technology Corporation
    Inventors: Richard D. Dimarchi, Binbin Kou, Fa Zhang, John P. Mayer
  • Publication number: 20190218268
    Abstract: Modified glucagon peptides are disclosed having improved solubility and/or stability while retaining glucagon agonist activity. The glucagon peptides have been modified by the substitution of pyridyl-alanine for a native amino acid at one or more of positions 6, 10 or 13 and/or substitution with an amino acid in the D-conformation at position 20 or 21 compared to native glucagon.
    Type: Application
    Filed: May 31, 2017
    Publication date: July 18, 2019
    Inventors: Richard D. DIMARCHI, John P. MAYER, Piotr MROZ
  • Publication number: 20190142963
    Abstract: Disclosed herein are modified C-terminal fragments of FGF21 optimized for binding to Klotho ? or antagonizing FGF21 activity. FGF21 peptides modified to comprise modifications to the C-terminal amino acid sequence are disclosed that have enhanced activity at the FGF21 receptor. Additionally, conjugates formed between the optimized FGF21 peptide fragments and insulin like peptides or nuclear hormone receptor ligands are provided.
    Type: Application
    Filed: April 14, 2017
    Publication date: May 16, 2019
    Inventors: Richard D. DIMARCHI, Alexei KHARITONENKOV, Pengyun LI, Archita S. AGRAWAL
  • Publication number: 20190127433
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 2, 2019
    Inventors: Richard D. DiMARCHI, David L. SMILEY
  • Patent number: 10232020
    Abstract: Disclosed herein are insulin agonist peptides conjugated to incretins wherein the incretin-insulin conjugate has agonist activity at the insulin receptor and the corresponding incretin receptor, and stimulates weight loss in an individual administered the compound.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: March 19, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, John P. Mayer, David L. Smiley, Fa Liu
  • Patent number: 10233225
    Abstract: Single chain insulin analogs are provided having high potency and specificity for the insulin receptor. As disclosed herein optimally sized linking moieties can be used to link human insulin A and B chains, or analogs or derivatives thereof, wherein the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the A1 amino acid of the A chain via the intervening linking moiety. In on embodiment the linking moiety comprises a polyethylene glycol of 6-16 monomer units and in an alternative embodiment the linking moiety comprises a non-native amino acid sequence derived form the IGF-1 C-peptide and comprising at least 8 amino acids and no more than 12 amino acid in length. Also disclosed are prodrug and conjugate derivatives of the single chain insulin analogs.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 19, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Yulia Azriel, Zachary Kaur, Jonathan Meyers, Todd Parody, Yan Zhao
  • Patent number: 10174093
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: January 8, 2019
    Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Richard D. DiMarchi, David L. Smiley
  • Patent number: 10137170
    Abstract: Herein is reported a fusion polypeptide comprising i) one, two, three or four incretin receptor ligand polypeptides, and ii) one human immunoglobulin Fc-region, wherein at least one of the incretin receptor ligand polypeptides comprises an amino acid that is covalently conjugated to a lipid, and wherein each of the one, two, three or four incretin receptor ligand polypeptides is covalently conjugated by a peptide bond to a terminus of the human immunoglobulin Fc-region, whereby to each terminus of the human immunoglobulin Fc-region only a single incretin receptor ligand polypeptide is conjugated.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: November 27, 2018
    Assignees: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, HOFFMANN-LA ROCHE INC.
    Inventors: Sara Belli, Konrad Bleicher, Richard D. Dimarchi, Eike Hoffmann, Eric A. Kitas, Anish A. Konkar
  • Publication number: 20180194827
    Abstract: Disclosed herein are insulin agonist peptides conjugated to a glucagon analog wherein the insulin/glucagon conjugate is targeted to liver tissues upon administration to a patient.
    Type: Application
    Filed: December 19, 2017
    Publication date: July 12, 2018
    Inventors: Richard D. DiMARCHI, Todd PARODY, Jie HAN, Pengyun LI
  • Publication number: 20180105569
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Application
    Filed: December 4, 2017
    Publication date: April 19, 2018
    Inventors: Richard D. DiMARCHI, David L. SMILEY, Konrad H. BLEICHER, Eric A. KITAS
  • Patent number: 9868772
    Abstract: Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: January 16, 2018
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. Dimarchi, David L. Smiley, Konrad H. Bleicher, Eric A. Kitas
  • Publication number: 20170349642
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Application
    Filed: August 7, 2017
    Publication date: December 7, 2017
    Inventors: Richard D. DiMARCHI, David L. SMILEY
  • Publication number: 20170313755
    Abstract: Disclosed herein are insulin analog conjugates comprising an insulin agonist covalently linked to an insulin antagonist peptide. The conjugates are high potency insulin agonists but with decreased maximal activity relative to the maximal activity of native insulin.
    Type: Application
    Filed: April 14, 2017
    Publication date: November 2, 2017
    Inventors: Richard D. DiMARCHI, Sarah J. BRANDT, Alexander ZAYKOV, Yan ZHAO
  • Patent number: 9790263
    Abstract: Glucagon peptides with increased GIP activity are provided, optionally with GLP-1 and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: October 17, 2017
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Tao Ma